期刊文献+

173例肺结核患者医院感染情况分析 被引量:2

Analysis of hospital infection of 173case pulmonary tuberculosis patients
下载PDF
导出
摘要 目的:探讨肺结核患者医院感染菌群分布及耐药情况,更好的指导临床用药。方法:收集我院2010年1月~2013年11月治疗的1668例肺结核患者资料,其中其中发生医院感染173例,进行细菌学分析。结果:173例医院感染的肺结核患者,真菌44株,占25.45%;G+球菌33株,占19.1%;G-杆菌96株,占55.8%。以革兰阴性杆菌为主,其次为真菌,G+球菌位居第三。33株G+球菌多数药物的的耐药率达75.8%,万古霉素的耐药率为0,44株真菌耐咪康唑16株,占36.4%,耐益康唑14株,占31.8%,耐酮康唑11株,25.0‰耐制霉菌素1株,占2.3‰耐两性霉素B1株,占2.3%,耐5-氟胞嘧啶1株,占2.3%。G-杆菌耐药率较高,氨苄西林、复方新诺明的耐药率在60%以上。结论:肺结核患者的各种细菌的耐药率较高,临床要根据药敏实验选择用药,减少药物的滥用。 Objective : To investigate the distribution of tuberculosis bacteria in patients with nosocomial infection and drug resistance, a better guide clinical practice. Methods : The hospital in January 2010- November 2013 Treatment of 1668 cases of tuberculosis patient data, including 173 cases of nosocomial infection which, for bacteriological analysis.Results : 173 cases of hospital infection in tuberculosis patients, fungi 44, accounting for 25.45%; G + cocci 33, accounting for 19.1%; G-bacteria 96, accounting for 55.8%. Gram-negative bacilli, followed by fungi, G + cocci in third place. 33 G + cocci majority of drug resistance rate of 75.8%, vancomycin-resistant strains of fungi resistant to miconazole was 0,44 16, 36.4%, resistance to econazole 14, 31.8%, resistance to ketoconazole 11, 25.0%, a resistance to nystatin, 2.3%, strains resistant to amphotericin B1, 2.3%, 52 flucytosine--resistant one, accounting for 2.3%. Higher rate of G-resistant bacteria, ampicillin, cotrimoxazole resistance rate of 60%. Conclusions : TB patients with a higher rate of bacterial resistance, susceptibility testing according to selected clinical medicine to reduce drug abuse.
作者 梁家银
出处 《医学检验与临床》 2016年第1期30-31,共2页 Medical Laboratory Science and Clinics
关键词 肺结核患者 医院感染 耐药分析 Pulmonary tuberculosis patients Hospital infections Drug resistance
  • 相关文献

参考文献1

二级参考文献7

  • 1黄晓军.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(草案)[J].中华内科杂志,2005,44(7):554-556. 被引量:423
  • 2Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709.
  • 3Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14.
  • 4Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240.
  • 5Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189.
  • 6Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200.
  • 7Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718.

共引文献865

同被引文献17

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部